

### Claims

- 1) A method for purifying and concentrating AAV-2 and antigen portions thereof, characterized in that AAV-2 or antigen portions thereof are bonded to an activated chromatographic material which comprises antibodies linked thereto and directed against AAV-2, and then elution is carried out using a solution containing 0.5 to 4.5 M  $\text{MgCl}_2$ .
- 2) The method according to claim 1, wherein AAV-2 is either wild-type AAV-2 or recombinantly prepared AAV-2.
- 3) The method according to claim 1 or 2, wherein the chromatographic material is selected from the group consisting of agarose gels, dextran gels, cellulose gel matrices and acrylamide gel matrices.
- 4) The method according to any one of claims 1 to 3, wherein the chromatographic material carries a ligand suitable for bonding proteins, particularly antibodies.
- 5) The method according to any one of claims 1 to 4, wherein the chromatographic material is CNBr-activated sepharose<sup>R</sup> or NHS-activated sepharose<sup>R</sup>.
- 6) The method according to any one of claims 1 to 5, wherein the elution solution contains 2 to 3 M  $\text{MgCl}_2$ .
- 7) The method according to any one of claims 1 to 6, wherein the sample containing the AAV-2 and rAAV-2, respectively, is a cell culture supernatant or cell extracts.
- 8) The method according to any one of claims 1 to 7, wherein the antibody directed against AAV-2 is A20 (DSM ACC2194).

- 9) A kit for carrying out the method according to any one of claims 1 to 8 comprising
- an antibody directed against AAV-2, and
  - conventional auxiliary agents, such as buffers, chromatographic material and controls.

098644-09001